Table 2

Predisposing factors of discontinuation of secukinumab

 Predictive factor Modality* Cox regression model Univariate Multivariate HR†(95% CI) P value HR(95% CI) P value Optimal report of a composite index‡ Yes: n=197No n=706 0.69(0.55 to 0.87) 0.002 070(0.55 to 0.88) 0.003 Centre size no of enrolled patients >10 patients: n=744≤10 patients: n=159 1.57(1.21 to 2.04) <0.001 1.50(1.16 to 1.95) 0.002 Age (years) >46 years: n=452≤46 years: n=451 0.80(0.67 to 0.96) 0.014 0.84(0.70 to 1.01) 0.060 Sex§ Female; n=523Male; n=380 1.24(1.03 to 1.48) 0.023 HLA B27 Positive; n=527Negative; n=298 0.91(0.76 to 1.10) 0.350 Smoking status Current; n=231Former; n=158Never; n=326 0.97(0.75 to 1.27) 0.849 Body mass index ≥30; n=133≥25–30; n=186≥18.5-<25; n=200<18.5; n=12 1.21(0.89 to 1.86) 0.228 Disease duration(years) >6.4 years: n=400≤6.4 years: n=405 0.84(0.69 to 1.01) 0.060 0.79(0.66 to 0.95) 0.011 Uveitis(past or present) Yes; n=131No; n=725 0.91(0.71 to 1.18) 0.483 IBD(past or present) Yes; n=22No; n=853 1.67(1.00 to 2.79) 0.051 1.82(1.08 to 3.06) 0.024 Psoriasis(past or present) Yes; n=194No; n=680 1.02(0.82 to 1.26) 0.876 Arthritis(past or present) Yes; n=258No; n=543 0.95(0.77 to 1.16) 0.600 Objective sign of inflammatin(at least one) Yes; n=616No; n=97 1.10(0.82 to 1.49) 0.524 Enthesitis(past or present) Yes; n=373No; n=530 0.87(0.72 to 1.06) 0.180 0.83(0.69 to 1.00) 0.045 Secukinumab line of therapy ≥3 rd: n=692first/2nd: n=204 1.24(0.99 to 1.55) 0.057 1.28(1.02 to 1.60) 0.033
• *The modality given in the second raw (eg, ‘No’ for ‘optimal report of a composite index’) defined the reference in the cox model.

• †HR (95% CI): HR and its (95% CI) (a value above one indicates a higher risk of discontinuation of secukinumab.

• ‡Reporting of a composite index=number of patients for whom a recommended composite index (either Bath Ankylosing Spndylitis Disease Activity Index (BASDAI)+CRP or Ankylosing Sondylitis Disease Avtivity Score (ASDAS) has been reported in the medical file at the time of initiation of secukinumab and at least once during the first year of follow-up.

• §This variable ‘sex’ was excluded during the stepwise logistic regression analysis (p=0.17).

• CRP, C reactive protein; IBD, inflammatory bowel disease.